Health

STAT+: Mark Cuban wants to crack open the market for rare disease treatments

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 21/10/2026, 08:36:25 UTC.

Briefings

Mark Cuban's Cost Plus Drugs company initiated a test of its custom-made rare disease medicine business model by receiving two shipments of DNA-like molecules. The first shipment contained molecules designed to repair a specific genetic mutation in a single patient's neurons, while the second contained molecules intended to halt muscle control loss in a rare disease affecting adults. Cuban stated in an email that the arrival of these treatments represented an obvious opportunity to assist patients with unfortunate conditions.

Key points

• Cost Plus Drugs received two shipments of DNA-like molecules for rare disease treatments.
• The first shipment targeted a genetic mutation destroying neurons in a single patient.

Context

Mark Cuban has spent five years attempting to lower costs for generic drugs like chemotherapy and antifungal ointment. This marks the company's first test of its vision for custom-made rare disease medicines, following earlier efforts to improve access to essential treatments.

Limitations

Evidence is limited to two specific shipments of DNA-like molecules; no patient names, specific mutation details, or treatment outcomes are provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 21/10/2026, 08:43:28 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihb67l2xjopqcpad3gzvp4mesczrd4h6slgqbf6firdhsaffpuece